Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 8:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 922 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Skin Manifestations Clear all
Terminated Phase 4 Interventional

Rituximab for the Otolaryngologic Manifestations of Granulomatosis With Polyangiitis

NCT02626845
View directory record Official record
Conditions
Granulomatosis With Polyangiitis (Wegener's Granulomatosis)
Interventions
Rituximab, Placebo
Drug · Other
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 21, 2018 · Synced Jul 23, 2026, 8:19 PM EDT
Completed Not applicable Interventional

Post Burn Pruritus Study in Patients Undergoing Wound Healing

NCT00137202
View directory record Official record
Conditions
Itching
Interventions
Ondansetron (Zofran), Diphenhydramine (Benadryl)
Drug
Lead sponsor
United States Army Institute of Surgical Research
Federal
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 27, 2008 · Synced Jul 23, 2026, 8:19 PM EDT
Completed Phase 2 Interventional

An Open-Label Clinical Trial of Replagal Enzyme Therapy in Children Ages 7-17 Years With Fabry Disease

NCT00071877
View directory record Official record
Conditions
Fabry Disease
Interventions
Replagal
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 23, 2026, 8:19 PM EDT
Withdrawn No phase listed Observational

Measurement of Carboxyhemoglobin by Gas Chromatography as an Index of Hemolysis

NCT00917007
View directory record Official record
Conditions
ABO Incompatibility, Hemolytic Disease of Newborn, Neonatal Jaundice, Neonatal Hyperbilirubinemia
Interventions
Not listed
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
Up to 28 Days
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Oct 24, 2021 · Synced Jul 23, 2026, 8:19 PM EDT
Completed Not applicable Interventional Results available

Reduced-Intensity Hematopoietic Stem Cell Transplant for High Risk Lysosomal and Peroxisomal Disorders

NCT01626092
View directory record Official record
Conditions
Lysosomal Storage Disease, Peroxisomal Disorder
Interventions
Campath-1H, Clofarabine, Melphalan, Total Body Irradiation with Marrow Boosting, Hematopoietic stem cell transplantation, Cyclosporine A, Mycophenolate mofetil
Drug · Radiation · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 55 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 4, 2017 · Synced Jul 23, 2026, 8:19 PM EDT
Completed Phase 1 Interventional

The Safety, Effectiveness, and Pharmacokinetics of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)

NCT01518907
View directory record Official record
Conditions
Edematous Fibrosclerotic Panniculopathy, Cellulite
Interventions
COLLAGENASE CLOSTRIDIUM HISTOLYTICUM
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
21 Years to 60 Years · Female only
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 18, 2015 · Synced Jul 23, 2026, 8:19 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis

NCT03504852
View directory record Official record
Conditions
Moderate to Severe Chronic Plaque-type Psoriasis
Interventions
secukinumab 150 mg
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
38
States / cities
Birmingham, Alabama • Phoenix, Arizona • Rogers, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2021 · Synced Jul 23, 2026, 8:19 PM EDT
Completed Not applicable Interventional

S1008: Exercise, Diet, & Counseling in Improving Weight Loss in Overweight Female Breast or Colorectal Cancer Survivors

NCT01453452
View directory record Official record
Conditions
Anxiety Disorder, Breast Cancer, Cognitive/Functional Effects, Colorectal Cancer, Depression, Fatigue, Pain, Psychosocial Effects of Cancer and Its Treatment, Weight Changes
Interventions
behavioral dietary intervention, exercise intervention, counseling intervention, quality-of-life assessment
Behavioral · Other · Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Up to 120 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
58
States / cities
Tucson, Arizona • Antioch, California • Fremont, California + 45 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Jul 23, 2026, 8:19 PM EDT
Terminated Phase 3 Interventional Results available

Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia

NCT02829814
View directory record Official record
Conditions
Fibromyalgia, Myofascial Pain Syndromes, Muscular Diseases, Nervous System Diseases, Neuromuscular Diseases, Rheumatic Diseases, Musculoskeletal Diseases
Interventions
TNX-102 SL Tablet, 2.8 mg, Placebo SL Tablet
Drug
Lead sponsor
Tonix Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
32
States / cities
Birmingham, Alabama • Phoenix, Arizona • Oceanside, California + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Jul 23, 2026, 8:19 PM EDT
Completed Phase 2 Interventional Results available

Cannabidiol (CBD) for Treatment of Aromatase Inhibitor-Associated Arthralgias

NCT04754399
View directory record Official record
Conditions
Arthralgia, Breast Cancer
Interventions
Cannabidiol (CBD)
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Jul 23, 2026, 8:19 PM EDT
Completed Not applicable Interventional Results available

The Utility of Peri-operative Arnica Montana for Reduction of Ecchymosis in Rhinoplasty Surgery

NCT01164644
View directory record Official record
Conditions
Ecchymosis
Interventions
Arnica montana, Placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 89 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Jul 23, 2026, 8:19 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

PatientSpot Formerly Known as ArthritisPower

NCT03840928
View directory record Official record
Conditions
Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout, Crohn Disease, Juvenile Idiopathic Arthritis, Lupus Erythematosus, Myositis, Osteoarthritis, Osteoporosis, Psoriasis, Psoriatic Arthritis, Scleroderma, Dermatomyositis, Inflammatory Bowel Diseases, Polymyositis, Axial Spondyloarthritis, Diffuse Idiopathic Skeletal Hyperostosis, Polymyalgia Rheumatica, Giant Cell Arteritis, Temporal Arteritis, Wegener, Relapsing Polychondritis, Undifferentiated Connective Tissue Disease, Spinal Cord Injuries, Alzheimer Disease, Amyotrophic Lateral Sclerosis, Ataxia, Bell Palsy, Brain Tumor, Cerebral Aneurysm, Epilepsy, Guillain-Barre Syndrome, Headache, Head Injury, Hydrocephalus, Lumbar Disc Disease, Meningitis, Multiple Sclerosis, Muscular Dystrophy, Neurocutaneous Syndromes, Parkinson Disease, Stroke, Cluster Headache, Tension-Type Headache, Chronic Obstructive Pulmonary Disease, Asthma, Lung Cancer, Cystic Fibrosis, Sleep Apnea, Eczema, Alopecia, Chronic Inflammation, Unstable Angina, Heart Attack, Heart Failure, Arrythmia, Valve Heart Disease, High Blood Pressure, Congenital Heart Disease, Peripheral Arterial Disease, Diabetes, Chronic Liver Disease, Obesity
Interventions
Not listed
Lead sponsor
Global Healthy Living Foundation
Other
Eligibility
19 Years and older
Enrollment
40,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
1
States / cities
Upper Nyack, New York
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Jul 23, 2026, 8:19 PM EDT
Recruiting No phase listed Observational

Vasculitis Pregnancy Registry

NCT02593565
View directory record Official record
Conditions
Vasculitis, Behcet's Disease, CNS Vasculitis, Cryoglobulinemic Vasculitis, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Churg-Strauss Syndrome (CSS), Granulomatosis With Polyangiitis (GPA), Wegener's Granulomatosis, IgA Vasculitis, Henoch-Schoenlein Purpura (HSP), Microscopic Polyangiitis (MPA), Polyarteritis Nodosa (PAN), Takayasu Arteritis (TAK), Urticarial Vasculitis, Systemic Vasculitis
Interventions
Online questionnaires
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Jul 23, 2026, 8:19 PM EDT
Completed Not applicable Interventional Results available

The Effect of Natrox® Oxygen Wound Therapy on the Healing Rate of Chronic Diabetic Foot Ulcers

NCT03905863
View directory record Official record
Conditions
Diabetic Foot Ulcer, Surgical Wound
Interventions
Natrox® Oxygen Wound Therapy
Device
Lead sponsor
Inotec AMD Limited
Industry
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
19
States / cities
Los Angeles, California • Miami, Florida • Miami Lakes, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2021 · Synced Jul 23, 2026, 8:19 PM EDT
Withdrawn Phase 2 Interventional

Psilocybin-Assisted Psychotherapy for Anxiety in People With Stage IV Melanoma

NCT00979693
View directory record Official record
Conditions
Anxiety, Stage IV Melanoma
Interventions
psilocybin
Drug
Lead sponsor
Multidisciplinary Association for Psychedelic Studies
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Miami Beach, Florida
Source: ClinicalTrials.gov public record
Updated Dec 25, 2023 · Synced Jul 23, 2026, 8:19 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Extended Platelet Parameters as a Means to Differentiate Immune Thrombocytopenia From Hypo-proliferative Thrombocytopenias.

NCT01933035
View directory record Official record
Conditions
Immune Thrombocytopenia, Chemotherapy Induced Thrombocytopenia, Myelodysplasia, Aplastic Anaemia
Interventions
Immune Thrombocytopenics, Hypo-proliferative thrombocytopenics, Control Population
Other
Lead sponsor
Beth Israel Medical Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Jul 23, 2026, 8:19 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and PK of ATTO-3712 in Healthy Volunteers and Patients With Atopic Dermatitis

NCT07205081
View directory record Official record
Conditions
Normal Volunteers, Atopic Dermatitis (AD), Atopic Eczema, Atopic Eczema/Dermatitis (Non-Specific)
Interventions
ATTO-3712, Placebo
Drug
Lead sponsor
Attovia Therapeutics Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Encinitas, California • Saint Joseph, Missouri
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Jul 23, 2026, 8:19 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids

NCT05653219
View directory record Official record
Conditions
Primary Immune Thrombocytopenia
Interventions
Ianalumab, Eltrombopag, Placebo
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
9
States / cities
Yuma, Arizona • Aurora, Colorado • Evanston, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Jul 23, 2026, 8:19 PM EDT
Not listed Not applicable Interventional

Light Exposure on Pain in Hypermobile Ehlers-Danlos Syndrome

NCT05561270
View directory record Official record
Conditions
Ehlers-Danlos Syndrome, Pain, Chronic
Interventions
White LED light, Green LED light
Device
Lead sponsor
New York Institute of Technology
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Old Westbury, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2024 · Synced Jul 23, 2026, 8:19 PM EDT
Recruiting Phase 1 Interventional

TENS in Scleroderma

NCT06646913
View directory record Official record
Conditions
Scleroderma, Gastroparesis, Systemic Sclerosis (SSc)
Interventions
Transcutaneous Electrical Nerve Stimulation
Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Jul 23, 2026, 8:19 PM EDT
Terminated Phase 3 Interventional

A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus

NCT05342623
View directory record Official record
Conditions
Chronic Kidney Diseases, Pruritus
Interventions
Difelikefalin 1 mg Oral Tablet, Placebo Oral Tablet
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
83
States / cities
Huntsville, Alabama • Phoenix, Arizona • Surprise, Arizona + 76 more
Source: ClinicalTrials.gov public record
Updated May 6, 2024 · Synced Jul 23, 2026, 8:19 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgia

NCT02436096
View directory record Official record
Conditions
Fibromyalgia, Myofascial Pain Syndromes, Muscular Diseases, Musculoskeletal Diseases, Nervous System Diseases, Neuromuscular Diseases, Rheumatic Diseases
Interventions
TNX-102 SL Tablet, 2.8mg, Placebo SL Tablet
Drug
Lead sponsor
Tonix Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
519 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
35
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sacramento, California + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Jul 23, 2026, 8:19 PM EDT
Completed Phase 2 Interventional Results available

Study of AKR-501 Tablets Taken Orally Once Daily for 28 Days in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP)

NCT00441090
View directory record Official record
Conditions
Chronic Idiopathic Thrombocytopenic Purpura, Purpura, Thrombocytopenic, Idiopathic
Interventions
Placebo, Avatrombopag tablets
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
25
States / cities
Anaheim, California • Bakersfield, California • Concord, California + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2018 · Synced Jul 23, 2026, 8:19 PM EDT
Completed No phase listed Observational

Comparison of the Skin Conductance Values and Patient Pain Scores During Minor Procedures in the ICU

NCT02276703
View directory record Official record
Conditions
Pain
Interventions
Skin Conductance Monitor
Device
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 89 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 14, 2017 · Synced Jul 23, 2026, 8:19 PM EDT